The Claim
Carrying rare loss-of-function variants in BRCA1 or BRCA2 genes is associated with a reduced lifespan, with hazard ratios of 2.2 and 2.4 respectively, based on analysis of 393,833 individuals of European ancestry from the UK Biobank; this association is driven by increased risk of cancer, particularly breast, ovarian, and other malignancies, consistent with the established roles of these genes in DNA repair and tumor suppression.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with rare harmful changes in the BRCA1 or BRCA2 genes tend to live shorter lives, mostly because they’re more likely to get cancers like breast and ovarian cancer.
See the scientific wording
Carrying rare loss-of-function variants in BRCA1 or BRCA2 is associated with reduced lifespan, with hazard ratios of 2.2 and 2.4 respectively, based on analysis of 393,833 individuals of European ancestry in the UK Biobank. These associations are driven by increased cancer risk, particularly breast, ovarian, and other malignancies, consistent with their established roles in DNA repair and tumor suppression.
What the research says
1 studyStudy: Rare genetic associations with human lifespan in UK Biobank are enriched for oncogenic genes
The study found that people with harmful BRCA1 or BRCA2 gene variants tend to live shorter lives, mostly because of higher cancer risk, which supports the main idea of the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.